title: Frequency of vitreomacular interface disease in patients presenting to a tertiary care institution.
abstract: OBJECTIVE
  To evaluate the frequency of vitreomacular interface disease using a recently published optical coherence tomography (OCT) classification and assess which of these patients would qualify for ocriplasmin.
  
  
  METHODS
  A retrospective, consecutive case series of patients with macular cyst, hole, or pseudohole (ICD-9 code 362.54) and concurrent OCT imaging was performed. Eyes were classified using OCT as pseudohole, lamellar hole, vitreomacular adhesion (VMA), vitreomacular traction (VMT), and full-thickness macular hole (FTMH). Minimum diameter (MD) of FTMH was measured.
  
  
  RESULTS
  The study included 399 eyes of 331 patients. Of these, 61 eyes (15.3%) had VMA or VMT, 120 (30.0%) had a lamellar hole or pseudohole, and 218 (54.6%) had FTMH. Of eyes with FTMH, 73 were small (< 250 µm MD), 48 were medium (250 to 400 µm MD), and 97 were large (> 400 µm MD). Overall, 68 eyes (17.0%) would be candidates for ocriplasmin therapy.
  
  
  CONCLUSIONS
  Most patients had FTMH, and 17% would qualify as candidates for ocriplasmin therapy.
authors.forename: Lucy T
authors.initials: LT
authors.lastname: Xu
authors.forename: Omar S
authors.initials: OS
authors.lastname: Punjabi
authors.forename: Jack
authors.initials: J
authors.lastname: Shao
authors.forename: Justis P
authors.initials: JP
authors.lastname: Ehlers
authors.forename: Sunil K
authors.initials: SK
authors.lastname: Srivastava
authors.forename: Rishi P
authors.initials: RP
authors.lastname: Singh
authors.forename: Peter K
authors.initials: PK
authors.lastname: Kaiser
mesh_terms: D000368:Aged; D001485:Basement Membrane / Q000473:pathology; D005260:Female; D005341:Fibrinolysin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008269:Macular Edema / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use; D012160:Retina / Q000473:pathology; D012167:Retinal Perforations / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy; D012189:Retrospective Studies; D062606:Tertiary Care Centers; D000267:Tissue Adhesions; D041623:Tomography, Optical Coherence; D014822:Vitreous Body / Q000473:pathology*; D020255:Vitreous Detachment / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin